#USA #Bio-Techne #Long Beach #RNAscope #Lunaphore

Bio-Techne Unveils Groundbreaking Advances in Spatial Biology

Bio-Techne Corporation, a leading name in life science tools, has made significant strides in the field of spatial biology. Recently, they announced enhancements to their spatial biology portfolio that promise to revolutionize translational research and clinical applications. The focus is on their two flagship technologies: RNAscope™ ISH technology and Lunaphore COMET™. These innovations are designed to facilitate the simultaneous detection of RNA and protein biomarkers on the same tissue section, thus enriching pathology workflows.

Bridging Research with Clinical Practice

The new advancements center around the potential of these technologies to help researchers and pathologists accurately identify clinically relevant biomarkers. For instance, RNAscope™ empowers professionals to detect critical indicators such as viral markers, secreted proteins, point mutations, and chromosomal translocations seamlessly within their regular anatomical pathology workflows. This capability is essential for ensuring meaningful diagnostics that cater to patient needs.

Lunaphore COMET™, on the other hand, focuses on providing fully automated, high-throughput hyperplex analysis for both RNA and protein biomarkers. This feature significantly enhances spatial multiomic workflows, thereby offering deeper biological insights that can influence treatment pathways and patient outcomes. With these tools, diagnostic challenges are met with cutting-edge technological solutions that promise to incorporate spatial biology into routine clinical practice.

Scientific Studies and Clinical Relevance

This season, substantial scientific investigations are set to explore the clinical utility of these innovative tools. For example, studies leveraging RNAscope™ for assessing B-cell clonality through IGLL5 detection and utilizing COMET™ for spatial profiling of lymphoid malignancies via a comprehensive 21-plex seqIF™ panel are gaining traction. These findings underscore the potential integration of spatial biology into diagnostic workflows, particularly in cases with limited tissue availability.

Bio-Techne will present these advances at the upcoming National Society of Histotechnology (NSH) Convention, scheduled from September 26 to 30, 2025, in Long Beach, California. Both Advanced Cell Diagnostics (ACD) and Lunaphore will have booths (#139 and #427) displaying these innovations. Their presentations will shed light on the groundbreaking applications and improvements that these technologies bring to the field.

Educational Presentations at NSH

1. RNAscope™ for Routine Anatomic Pathology: Dr. Ryan Bremer will discuss the advantages of RNAscope™ over traditional RNA ISH methods. His insights will outline how seamlessly RNAscope can be incorporated into existing workflows, making it an ideal choice for pathologists. (Session WS29, Sep. 27, 4:45 p.m.)

2. Insights into B-cell Clonality with RNAscope™: Selected for a live presentation, Dr. Ishani Das will emphasize the comparative performance of RNAscope™ in assessing B-cell clonality using immunoglobulin kappa and lambda light chain markers, highlighting concurrent detection capabilities unique to RNAscope. (Poster #6038, Sep. 30, 9:05–9:20 a.m.)

3. Spatial Profiling of Lymphoid Malignancies with seqIF™ Panel: Dr. Antonio Sorrentino’s poster will showcase how COMET technology enhances lymphoid malignancy diagnosis, bridging B-cell lymphoma workflows while preserving precious tissue samples from biopsies. (Poster #6043)

Future Collaborations

Bio-Techne continues to deepen its collaboration with Leica Biosystems by co-hosting a waterfront reception on September 28 at Parker's Lighthouse. This event will provide attendees with an opportunity to network and engage with RNAscope assays implemented on Leica BOND platforms.

Dr. Matt McManus, President of the Diagnostics and Spatial Biology Segment of Bio-Techne, expressed enthusiasm over their progress, stating, "We are thrilled by the advancements we’ve made in traditional in situ hybridization. Collaborating with our clients and learning from the exceptional speakers at NSH is paving the way for innovative tools that brings us closer to unraveling the molecular drivers of disease and revolutionizing patient care."

Conclusion

As Bio-Techne continues to chart a course toward enhancing diagnostic capabilities and patient outcomes, the commitment to innovation within the realm of spatial biology remains clear. With a comprehensive suite of tools, Bio-Techne stands poised to influence the future of diagnostic pathology, ensuring that researchers and healthcare providers have the best resources at their disposal for accurate and timely patient care.

For additional information about Bio-Techne and their trailblazing technologies, visit their website Bio-Techne or follow them on social media platforms like LinkedIn, X, and YouTube.